ARTELO BIOSCIENCES, INC.

ARTL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-12.9M $-9.8M $-9.3M $-10.1M $-9.4M $-4.7M $-2.2M $-2.3M
Depreciation & Amortization
Depreciation $500 $510 $282
Amortization
Stock-Based Compensation $1.1M $818.0K $1.0M $2.5M $1.5M $381.0K $425.1K $290.0K
Net Cash from Operating Activities $-8.5M $-8.4M $-8.2M $-8.0M $-6.1M $-4.3M $-2.8M $-1.6M
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities $-62.0K $7.8M $3.5M $3.0M $-3.4M $0 $-1.5M $-845
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $6.9M $112.0K $567.0K $0 $14.1M $2.0M $8.4M $1.4M
Net Change in Cash $-1.7M $-477.0K $-4.1M $-5.3M $4.5M $-2.3M $4.1M $-235.4K
Free Cash Flow
← Newer Page 1 of 2 Older →